Research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the stock.
Bio-Path Price Performance
Shares of BPTH stock opened at $1.04 on Thursday. The stock’s 50 day simple moving average is $0.89 and its 200 day simple moving average is $1.26. Bio-Path has a twelve month low of $0.59 and a twelve month high of $12.00.
Hedge Funds Weigh In On Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.74% of the company’s stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also
- Five stocks we like better than Bio-Path
- How to Read Stock Charts for Beginners
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- Want to Profit on the Downtrend? Downtrends, Explained.
- 2 Drone Stocks Surging from Increased Media Attention
- What Are Trending Stocks? Trending Stocks Explained
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
